ABSTRACT

Introduction:

Supraventricular tachycardia is the most common cause of arrhythmia in children. The aim of this study was to determine the dose and efficacy of adenosine treatment in the management of supraventricular tachycardia and to determine the factors affecting response to treatment.

Methods:

Patients diagnosed with supraventricular tachycardia between January 2010 and December 2015 were evaluated retrospectively. Medical history of the patients, vital signs, physical findings, treatment, number of adenosine administration and treatment responses were recorded. The patients were divided into two groups: those responding to the first dose of adenosine treatment and those not responding. These two groups were compared in terms of demographic and clinical features.

Results:

A total of 30 patients (17 male, 13 female) aged 2-180 months were evaluated. Vagal maneuvers were performed as initial treatment in 13 patients. Five patients (38%) responded to vagal maneuver. Twenty-four patients (80%) received adenosine treatment and 23 (95.8%) responded to treatment. Of the 23 patients, who responded to adenosine treatment, 14 (60.8%) responded to the first dose, six (26%) to the second dose, and 3 patients (13%) to the third dose. The total adenosine dose in the responders was 0.15 mg/kg (minimum: 0.1, maximum: 0.5). No side effects associated with adenosine treatment were observed. The age of responders to the first dose of adenosine was found to be greater than others (102 months vs. 5 months) (p<0.05).

Conclusion:

Adenosine is an effective and safe drug in the treatment of supraventricular tachycardia. However, response to the initial dose of 0.1 mg/kg adenosine is significantly lower in children younger than one year. We think that the first adenosine dose should be increased. However, further large-scale randomized controlled trials are warranted.

Keywords: Adenosine, pediatric emergency department, supraventricular tachycardia

References

Dıaz-Parra S, Sanchez-Yanez P, Zabala-Arguelles I, Picazo-Angelin B, Conejo-Muñoz L et al. Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department. Pediatr Emerg Care. 2014;30:388-93

Misaki T, Watanabe G, Iwa T, Watanabe Y, Mukai K, et al. Surgical treatment of patients with wolff-parkinson-white syndrome and associated ebstein’s anomaly. J Thorac Cardiovasc Surg. 1995;110:1702-7.

Khositseth A, Danielson GK, Dearani JA, Munger TM, Porter CJ. Supraventricular tachyarrhythmias in ebstein anomaly: management and outcome. J Thorac Cardiovasc Surg. 2004;128:826-33.

Maconochie IK, Bingham R, Eich C, López-Herce J, Rodríguez-Núñez A, et al. Paediatric life support section collaborators. European Resuscitation Council Guidelines for Resuscitation 2015: Section 6. Paediatric life support. Resuscitation. 2015;95:223-48.

Ko JK, Deal BJ, Strasburger JF, Benson DW. Supraventricular tachycardia and their distribution in pediatric patients. Am J Cardiol. 1992;69:1028-32.

Perry JC, Garson A Jr. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol. 1990;16:1215-20.

Anon. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10: pediatric advanced life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102(8 Suppl):I291-342.

Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S876-908.

Delacrétaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. 2006;354:1039-51.

Müller G, Deal BJ, Benson DW. Vagal maneuvers and adenosine for termination of atrioventriculer reenrant tachycardia. Am J Cardiol. 1994;74:500-3.

Lewis J, Arora G, Tudorascu DL, Hickey RW, Saladino RA, et al. Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia. J Pediatr. 2017;181:177-82.

RCPCH. Medicines for children, 2nd edn. London: RCPCH Publications Limited, 2003.

Mackway-Jones K, Molyneux E, Phillips B, Wieteska S. Advanced paediatric life support. The practical approach, 3rd edn. London: BMJ Books,2001.

Clausen H, Theophilos T, Jackno K, Babl FE. Paediatric arrhythmias in the emergency department. Emerg Med J. 2012;29:732-7.

Gandhi A, Uzun O. Adenosine dosing in supraventricular tachycardia: time for change. Arch Dis Child. 2006;91:373.

Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, et al. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33:185-91.

Dixon J, Foster K, Wyllie J. Guidelines and adenosine dosing in supraventricular tachycardia. Arch Dis Child. 2005;90:1190-91.

Quail MA, Till J. Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child. 2012;97:177-9.

Bibas L, Levi M, Essebag V. Diagnosis and management of supraventricular tachycardias. CMAJ. 2016;188:17-8.

Supraventricular Tachycardia Treatment in the Pediatric Emergency Department: Evaluation of Adenosine Dose and Treatment Response

ABSTRACT

References